| Pharmacokinetics  | è�¯åЍå¦ã€€ |
| An appropriate response to a drug requires the appropriate concentration of drug at the site of action. The dosage regimen required to attain and maintain the appropriate concentration depends on pharmacokinetics. The appropriate concentration and dosage regimen depend on the patient's clinical state, severity of the disorder, presence of concurrent disease, use of other drugs, and other factors.  | è�¯ç‰©è¦�获得适宜的效应,就需è¦�在作用部ä½�达到适当的è�¯ç‰©æµ“度。达到和维æŒ�适当è�¯ç‰©æµ“度所需è¦�的给è�¯æ–¹æ¡ˆåº”è¯¥æ ¹æ�®è�¯ç‰©ä»£è°¢åŠ¨åŠ›å¦åˆ¶å®šã€‚适当的浓度和给è�¯æ–¹æ¡ˆä¹Ÿå�–决于病人的临床状æ€�ã€�疾病的严é‡�程度ã€�æœ‰æ— å¹¶å�‘疾病ã€�å…¶ä»–è�¯ç‰©ä½¿ç”¨æƒ…况以å�Šå…¶ä»–å› ç´ ã€‚ã€€ |
| Because of individual differences, drug administration must be based on each patient's needs--traditionally, by empirically adjusting dosage until the therapeutic objective is met. This approach is frequently inadequate because optimal response may be delayed or serious toxic reactions may occur. Alternatively, a drug can be administered according to its expected absorption and disposition (distribution and elimination) in a patient, and dosage can be adjusted by monitoring plasma drug concentration and drug effects. This approach requires knowledge of the drug's pharmacokinetics as a function of the patient's age and weight and the kinetic consequences of concurrent diseases (eg, renal, hepatic, or cardiovascular disease or a combination of diseases).  | 由于个体差异的å˜åœ¨ï¼Œç»™è�¯æ–¹æ¡ˆå°±é¡»æ ¹æ�®æ¯�一个病人的需è¦�æ�¥è®¾å®šã€‚ä¼ ç»Ÿä¸Šçš„å�šæ³•æ˜¯å‡ç»�验ä¸�æ–调整剂é‡�,一直到达到治疗目的为æ¢ã€‚è¿™ç§�方法由于å�¯èƒ½å»¶è¯¯æœ€ä¼˜è�¯ç‰©æ•ˆåº”或导致严é‡�毒性å��应,通常并ä¸�å�ˆé€‚。å�¦å¤–一ç§�å�šæ³•æ˜¯æ ¹æ�®è�¯ç‰©åœ¨æŸ�一病人体内的预期å�¸æ”¶å’Œå¤„置过程(分布和消除)用è�¯ï¼Œé€šè¿‡ç›‘测血浆è�¯ç‰©æµ“度以å�Šè§‚察è�¯ç‰©æ•ˆåº”æ�¥è°ƒæ•´ç”¨è�¯å‰‚é‡�,采å�–这一å�šæ³•ï¼Œå°±å¿…é¡»æ‡‚å¾—è�¯ä»£åŠ¨åŠ›å¦ï¼ŒçŸ¥é�“它是éš�病人年龄和体é‡�而å�˜åŒ–的,å�Œæ—¶è¿˜è¦�懂得并å�‘疾病(如肾病ã€�è‚�ç—…ã€�心血管疾病或其他并å�‘疾病)的动力å¦å�Žæžœã€‚  |
| Basic Pharmacokinetic Parameters  | è�¯ç‰©ä»£è°¢åŠ¨åŠ›å¦åŸºæœ¬å�‚数  |
| The pharmacokinetic behavior of most drugs can be summarized by the following parameters. The parameters are constants, although their values may differ from patient to patient and in the same patient under different conditions.  | 大多数è�¯ç‰©çš„è�¯ä»£åŠ¨åŠ›å¦ä½œç”¨å�¯ç”¨ä¸‹åˆ—å�‚æ•°åŠ ä»¥å½’çº³ã€‚è¿™äº›å�‚æ•°å�‡ä¸ºå¸¸æ•°ï¼Œä½†å�‚æ•°å€¼ä¹Ÿä¼šå› äººè€Œå¼‚ï¼Œè€Œä¸”å�Œä¸€ç—…人在ä¸�å�Œæƒ…况下亦会有所ä¸�å�Œã€‚  |
| Bioavailability expresses the extent of drug absorption into the systemic circulation. The absorption rate constant expresses the speed of absorption. These parameters influence the maximum (peak) concentration, the time at which the maximum concentration occurs (peak time), and the area under the concentration-time curve (AUC) after a single oral dose. During long-term drug therapy, the extent of absorption is the more important measurement because average concentration depends on it; the degree of fluctuation is related to the absorption rate constant.  | 生物利用度表示è�¯ç‰©å�¸æ”¶è¿›å…¥ä½“循环的分é‡�。å�¸æ”¶é€ŸçŽ‡å¸¸æ•°è¡¨ç¤ºå�¸æ”¶çš„速度。这些å�‚数会影å“�å�•剂å�£æœ�å�Žçš„æœ€å¤§ï¼ˆå³°ï¼‰æµ“度,到达最大浓度的时间以å�Šæµ“度-时间曲线下é�¢ç§¯ã€‚在长期è�¯ç‰©æ²»ç–—期间,å�¸æ”¶çš„分é‡�测é‡�æŒ‡æ ‡æ›´é‡�è¦�ï¼Œå› ä¸ºå¹³å�‡æµ“åº¦å°±æ˜¯æ ¹æ�®å®ƒæ�¥è®¡ç®—的,而浓度的波动程度则与å�¸æ”¶é€ŸçŽ‡å¸¸æ•°æœ‰å…³ã€‚ã€€ |
| The apparent volume of distribution is the amount of fluid that would be required to contain the drug in the body at the same concentration as in the blood or plasma. It can be used to estimate the dose required to produce a given concentration and the concentration expected for a given dose. The unbound concentration is closely associated with drug effects, so unbound fraction is a useful measure, particularly when plasma protein binding is altered--eg, by hypoalbuminemia, renal or hepatic disease, or displacement interactions. The apparent volume of distribution and the unbound fraction in plasma are the most widely used parameters for drug distribution.  | 表观分布容积是指使体内è�¯ç‰©æµ“åº¦ä¸Žè¡€æ¶²æˆ–è¡€æµ†å†…æµ“åº¦ç›¸ç‰æ—¶æ‰€éœ€è¦�的液体容é‡�。该å�‚æ•°å�¯ç”¨ä»¥è®¡ç®—获得一定浓度所需的剂é‡�å�Šä¸€å®šå‰‚é‡�å�Žå�¯è¾¾åˆ°çš„血浓度。é�žç»“å�ˆåž‹è�¯ç‰©æµ“度与è�¯ç‰©æ•ˆåº”å¯†åˆ‡ç›¸å…³ï¼Œå› æ¤ï¼Œé�žç»“å�ˆåž‹åˆ†æ•°æ˜¯ä¸€ä¸ªæœ‰ç”¨çš„æµ‹é‡�æŒ‡æ ‡ï¼Œç‰¹åˆ«æ˜¯å½“è¡€æµ†è›‹ç™½ç»“å�ˆæ”¹å�˜æ—¶ï¼Œå¦‚低蛋白血症ã€�肾病ã€�è‚�病引起的改å�˜æˆ–è�¯ç‰©ç›¸äº’ç½®æ�¢ä½œç”¨å¼•起的改å�˜ã€‚表观分布容积和血浆é�žç»“å�ˆåˆ†æ•°æ˜¯è�¯ç‰©åˆ†å¸ƒä¸ç”¨å¾—最广的å�‚数。  |
| The rate of elimination of a drug from the body varies with the plasma concentration. The parameter relating elimination rate to plasma concentration is total clearance, which equals renal clearance plus extrarenal (metabolic) clearance.  | �物从体内消除的速率�血浆浓度而改�。将消除速率和血浆浓度�系起�的�数就是总清除率。总清除率为肾清除率与肾外(�代谢)清除率之和。  |
| The fraction excreted unchanged helps assess the potential effect of renal and hepatic diseases on drug elimination. A low fraction indicates that hepatic metabolism is the likely mechanism of elimination and that hepatic disease may therefore affect drug elimination. Renal diseases produce greater effects on the kinetics of drugs with a high fraction excreted unchanged.  | 原型排泄分数有助于评估肾病或è‚�病对è�¯ç‰©æ¶ˆé™¤çš„æ½œåœ¨å½±å“�。低分数表明è‚�è„�代谢很å�¯èƒ½æ˜¯è�¯ç‰©çš„æ¶ˆé™¤æœºåˆ¶ï¼Œå› 而,è‚�è„�疾病å�¯ä»¥å½±å“�è�¯ç‰©çš„æ¶ˆé™¤ã€‚肾è„�疾病对高原型排泄分数è�¯ç‰©çš„代谢动力å¦å½±å“�较大。  |
| The extraction rate of a drug from the blood by an eliminating organ, such as the liver, cannot exceed the rate of drug delivery to the organ. Thus, clearance has an upper limit, based on drug delivery and hence on blood flow to the organ. Furthermore, when the eliminating organ is the liver or gut wall and a drug is given orally, part of the dose may be metabolized as it passes through the tissues to the systemic circulation; this process is called first-pass metabolism. Thus, if extraction (clearance) of a drug is high in the liver or gut wall, oral bioavailability is low, sometimes precluding oral administration or requiring an oral dose much larger than an equivalent parenteral dose. Drugs with extensive first-pass metabolism include alprenolol, hydralazine, isoproterenol, lidocaine, meperidine, morphine, nifedipine, nitroglycerin, propranolol, testosterone, and verapamil.  | 消除器官(如è‚�è„�ï¼‰ä»Žè¡€æ¶²ä¸æ��å�–è�¯ç‰©çš„速率ä¸�能超过è�¯ç‰©è¾“å�‘è¯¥å™¨å®˜çš„é€ŸçŽ‡ï¼Œè¿™æ ·ï¼Œæ¸…é™¤çŽ‡å°±æœ‰ä¸€ä¸ªä¸Šé™�,ä¸�能脱离è�¯ç‰©çš„输é€�,自然也ä¸�能脱离æµ�入该器官的血æµ�é‡�。而且,当消除器官为è‚�è„�å’Œè‚ å£�ã€�è�¯ç‰©å�ˆæ˜¯å�£æœ�时,部分è�¯ç‰©åœ¨é€�过组织进入体循环之时就会被代谢,这一过程就称为首关代谢。如果一ç§�è�¯ç‰©åœ¨è‚�è„�å’Œè‚ å£�çš„æ��å�–率(清除率)高,那么,它å�£æœ�时的生物利用度就低,这时,就è¦�é�¿å…�å�£æœ�ç»™è�¯ï¼Œæˆ–在å�£æœ�æ—¶è¦�åŠ å¤§å‰‚é‡�ï¼Œä½¿å…¶é«˜äºŽèƒƒè‚ é�“外的用è�¯å‰‚é‡�。首关代谢明显的è�¯ç‰©åŒ…括:阿普洛尔ã€�肼屈嗪ã€�å¼‚ä¸™è‚¾ä¸Šè…ºç´ ã€�利多å�¡å› ã€�哌替啶ã€�å�—å•¡ã€�ç¡�苯地平ã€�ç¡�酸甘油ã€�æ™®è�˜æ´›å°”ã€�ç�¾é…®å’Œç»´æ‹‰å¸•米。  |
| The elimination rate constant is a function of how a drug is cleared from the blood by the eliminating organs and how the drug distributes throughout the body.  | 消除速率常数是表示è�¯ç‰©è¢«æ¶ˆé™¤å™¨å®˜ä»Žè¡€æ¶²ä¸æ¸…除å�Šè¯¥è�¯ç‰©åœ¨ä½“内分布情况的一个函数。  |
| Half-life (elimination) is the time required for the plasma drug concentration or the amount of drug in the body to decrease by 50%. For most drugs, half-life remains the same regardless of how much drug is in the body. Exceptions include phenytoin, theophylline, and heparin.  | å�Šè¡°æœŸï¼ˆæ¶ˆé™¤ï¼‰æ˜¯æŒ‡è¡€æµ†è�¯ç‰©æµ“度或体内è�¯ç‰©æ•°é‡�é™�低50%时所需的时间。对多数è�¯ç‰©è€Œè¨€ï¼Œä¸�管它在体内有多少,它的å�Šè¡°æœŸéƒ½æ˜¯ç›¸å�Œçš„。å�ªæœ‰è‹¯å¦¥è‹±ã€�茶碱和è‚�ç´ æ˜¯ä¾‹å¤–ã€‚ã€€ |
| Mean residence time (MRT), another measure of drug elimination, is the average time a drug molecule remains in the body after rapid IV injection. Like clearance, its value is independent of dose. After an IV bolus,  | å¹³å�‡é©»ç•™æ—¶é—´ï¼ˆMRT)是表示è�¯ç‰©æ¶ˆé™¤çš„å�ˆä¸€ä¸ªæµ‹é‡�值,是指æŸ�ç§�è�¯ç‰©å¿«é€Ÿé�™æ³¨å�Žï¼Œå…¶è�¯ç‰©åˆ†å�滞留在体内的平å�‡æ—¶é—´ã€‚å’Œæ¸…é™¤çŽ‡ä¸€æ ·ï¼Œå®ƒä¹Ÿä¸�爱剂é‡�的影å“�。快速é�™æ³¨å�Žçš„å¹³å�‡é©»ç•™æ—¶é—´è®¡ç®—å…¬å¼�为:  |
| MRT�AUMC�AUC  | MRT�AUMC�AUC  |
| AUMC is the area under the first moment of the plasma concentration-time curve. For a drug with one-compartment distribution characteristics, MRT equals the reciprocal of the elimination rate constant.  | å…¶ä¸AUMC是指一阶矩血浆浓度时间曲线下é�¢ç§¯ã€‚对具有一室分布特å¾�çš„è�¯ç‰©æ�¥è¯´ï¼ŒMRTç‰äºŽæ¶ˆé™¤é€ŸçŽ‡å¸¸æ•°çš„å€’æ•°ã€‚ã€€ |